iCAD (NASDAQ:ICAD) Releases Earnings Results, Beats Expectations By $0.01 EPS

iCAD (NASDAQ:ICAD) announced its quarterly earnings data on Thursday. The technology company reported ($0.09) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.10) by $0.01, Morningstar.com reports. iCAD had a negative net margin of 36.24% and a negative return on equity of 54.45%. The company had revenue of $7.33 million for the quarter, compared to the consensus estimate of $6.69 million.

ICAD stock traded down $0.09 during trading on Friday, hitting $6.74. 139,680 shares of the stock traded hands, compared to its average volume of 111,550. iCAD has a 1 year low of $2.42 and a 1 year high of $7.45. The stock has a 50 day simple moving average of $6.42. The stock has a market capitalization of $122.70 million, a PE ratio of -17.74 and a beta of 1.18. The company has a current ratio of 1.47, a quick ratio of 1.33 and a debt-to-equity ratio of 2.90.

A number of hedge funds have recently made changes to their positions in the stock. Advisor Group Inc. boosted its holdings in shares of iCAD by 96,087.0% during the 4th quarter. Advisor Group Inc. now owns 22,123 shares of the technology company’s stock valued at $82,000 after acquiring an additional 22,100 shares during the last quarter. Spark Investment Management LLC purchased a new stake in shares of iCAD during the 1st quarter valued at about $185,000. Deutsche Bank AG boosted its holdings in shares of iCAD by 33.5% during the 4th quarter. Deutsche Bank AG now owns 35,923 shares of the technology company’s stock valued at $132,000 after acquiring an additional 9,023 shares during the last quarter. Columbia Pacific Advisors LLC boosted its holdings in shares of iCAD by 218.0% during the 1st quarter. Columbia Pacific Advisors LLC now owns 63,600 shares of the technology company’s stock valued at $329,000 after acquiring an additional 43,600 shares during the last quarter. Finally, EAM Global Investors LLC purchased a new stake in shares of iCAD during the 1st quarter valued at about $984,000. 18.98% of the stock is currently owned by institutional investors.

Separately, ValuEngine downgraded shares of iCAD from a “buy” rating to a “hold” rating in a research report on Thursday.

iCAD Company Profile

iCAD, Inc provides image analysis, workflow solutions, and radiation therapy for the early identification and treatment of cancer in the United States and internationally. It operates through two segments, Cancer Detection and Cancer Therapy. The company provides electronic brachytherapy (eBX) products, including Axxent eBx systems for the treatment of early stage breast cancer, endometrial cancer, cervical cancer, and skin cancer, as well as for treating other cancers or conditions where radiation therapy is indicated comprising intraoperative radiation therapy.

Further Reading: Why are analyst ratings important in trading stocks?

Earnings History for iCAD (NASDAQ:ICAD)

Receive News & Ratings for iCAD Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iCAD and related companies with MarketBeat.com's FREE daily email newsletter.